Adam’s Take

Insights and opinions from senior biotech writer Adam Feuerstein

Adam's Take

Preclinical biotech companies are having an IPO bonanza. What’s the draw for investors?

By Adam Feuerstein

Celgene
Adam's Take

Celgene is perking up. Here’s what needs to happen for the momentum to continue

By Adam Feuerstein

Adam's Take

Red flags fly over Anavex: What’s stopping the drug maker from enrolling U.S., European patients in trials?

By Adam Feuerstein

Human stem cell BrainStorm
Adam's Take

ALS drug maker walks back plan to profit from right-to-try law following heavy criticism

By Adam Feuerstein

Pablo Ross
Adam's Take

Here come the right-to-try profiteers. The FDA is powerless to stop them

By Adam Feuerstein

Red blood cells
Adam's Take

Geron wants J&J to continue a drug development partnership, but new data weaken its case

By Adam Feuerstein

Fatty Liver Drawing
Adam's Take

Questionable data aside, Galmed Pharma soars in a fatty liver stock bubble

By Adam Feuerstein

Chest X-ray pneumonia
Adam's Take

Proteostasis cystic fibrosis drug disappoints, easing competitor concerns for Vertex Pharma

By Adam Feuerstein

Omeros Bone Marrow
Adam's Take

Omeros is bullish on its plan for speedy approval of a rare disease drug. Its plan has flaws

By Adam Feuerstein

Adam's Take

A deeply troubled drug company fires its CEO, who then unfires himself. Comedy, chaos ensue

By Adam Feuerstein

Adam's Take

After watching Trump’s drug speech, investors poured big money into biotech funds

By Adam Feuerstein

Adam's Take

Biotech stocks open higher Monday on ‘Trump bump’

By Adam Feuerstein

Adam's Take

Biotech updates: Amicus, Aveo Oncology, Akcea Therapeutics, and Ionis Pharma

By Adam Feuerstein

Celgene
Adam's Take

A strong Celgene earnings report gives investors reasons to start trusting again

By Adam Feuerstein

Adam's Take

Gilead’s ‘trough year’ looking harder to dig out from after miserable first quarter

By Adam Feuerstein

Celgene
Adam's Take

Celgene’s beaten-down stock is cheap, but only if investors regain trust in its financial outlook

By Adam Feuerstein

Cash
Adam's Take

This biotech CEO’s lousy job performance cost shareholders money, so his board docked his pay

By Adam Feuerstein

Adam's Take

SEC extends probe into Northwest Biotherapeutics as financial struggles mount

By Adam Feuerstein

Adam's Take

Biogen and the badly needed gene therapy acquisition that got away

By Adam Feuerstein

Adam's Take

Experimental drug might reduce fat in blood, but a NASH cure? Not so fast

By Adam Feuerstein

Adam's Take

Biotech saw positive results this quarter; shares still tanked. Here are some explanations

By Adam Feuerstein

Adam's Take

The top-performing biotech stock this year has surged on flimsy data

By Adam Feuerstein

peanuts
Adam's Take

AnaptysBio peanut allergy shot improves tolerance, aided by generous reading of data

By Adam Feuerstein

IP Phone
Adam's Take

Biotech CEOs talk a lot. Here’s how to spot the red flags in what they’re saying

By Adam Feuerstein

Martin Shkreli & Benjamin Brafman
Adam's Take

Martin Shkreli has been sentenced. The drug industry is trying to get away scot-free

By Adam Feuerstein

Kopy Katz
Adam's Take

Marinus Pharma finds the biotech imitation game can only last so long

By Adam Feuerstein

Killer T cells surround a cancer cell
Adam's Take

A biotech seeking IPO riches limited disclosure of patient deaths tied to immunotherapy

By Adam Feuerstein

Adam's Take

Omeros cataract surgery drug sales vanished and now a loan default is a real risk

By Adam Feuerstein

Chest thumping
Adam's Take

Biotech is full of chest-thumping press releases. This one thumps really hard

By Adam Feuerstein and Damian Garde

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy